Skip to main content
. Author manuscript; available in PMC: 2013 Oct 22.
Published in final edited form as: N Engl J Med. 2012 Dec 13;367(24):2305–2315. doi: 10.1056/NEJMoa1207285

Table 1.

Demographic and Clinical Characteristics of the Patients and Controls.*

Characteristic Patients Controls
Haploidentical
Mesenchymal
Stromal Cells
(N = 7)
STRO-3+
Mesenchymal
Progenitor Cells
(N = 24)
MDACC
(N = 60)
CIBMTR
(N = 80)
Weight — kg
   Median 79 75 75 82
   Range 53–95 51–118 48–122 40–170
Age — yr
   Median 31 39 32 36
   Range 26–55 18–61 18–64 18–61
Diagnosis — no. (%)
   AML or MDS 5 (71) 16 (67) 31 (52) 52 (65)
   ALL 1 (14) 4 (17) 15 (25) 20 (25)
   Non-Hodgkin’s or Hodgkin’s lymphoma 0 3 (12) 5 (8) 7 (9)
   CLL 1 (14) 1 (4) 2 (3) 1 (1)
   CML or other MPD 0 0 6 (10) 0
   Myeloma 0 0 1 (2) 0
   Disease status at time of transplantation — no. (%)
   Complete remission 1 (14) 12 (50) 26 (43) 49 (61)
     First remission 1 (14) 2 (8) 8 (13) 17 (21)
     Second or subsequent remission 0 10 (42) 18 (30) 32 (40)
   Active disease 6 (86) 12 (50) 34 (57) 31 (39)
Donor–recipient HLA compatibility — no. (%)
   6/6 0 1 (4) 4 (7) 4 (5)
   5/6 3 (43) 3 (12) 13 (22) 14 (18)
   4/6 4 (57) 20 (83) 43 (72) 58 (72)
   3/6 0 0 0 2 (2)
   Not reported 0 0 0 2 (2)
*

ALL denotes acute lymphocytic leukemia, AML acute myeloid leukemia, CIBMTR Center for International Blood and Marrow Transplant Research, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, and MPD myeloproliferative disorder.

Two controls from the M.D. Anderson Cancer Center (MDACC) were excluded owing to lack of engraftment and chimerism documentation.

HHS Vulnerability Disclosure